Literature DB >> 18195590

Topiramate does not alter nicotine or cocaine discrimination in rats.

Bernard Le Foll1, Zuzana Justinova, Carrie E Wertheim, Chanel Barnes, Steven R Goldberg.   

Abstract

The effects of topiramate, a potential treatment for drug dependence, were evaluated in two groups of rats trained to discriminate the administration of either 0.4 mg/kg nicotine or 10 mg/kg cocaine from that of saline, under a fixed-ratio 10 schedule of food delivery. Topiramate (1-60 mg/kg, intraperitoneal) did not produce any nicotine-like or cocaine-like discriminative effects by itself and did not produce any shift in the dose-response curves for nicotine or cocaine discrimination. Thus, the ability to discriminate the effects of nicotine or cocaine does not appear to be altered by topiramate administration. Furthermore, topiramate, given either alone or in combination with nicotine or cocaine, did not depress rates of responding. These experiments indicate that topiramate does not enhance or reduce the ability of rats to discriminate the effects of nicotine or cocaine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195590      PMCID: PMC2682733          DOI: 10.1097/FBP.0b013e3282f3cf84

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  50 in total

1.  Pharmacotherapy and other treatments for cocaine abuse and dependence.

Authors:  Frank J Vocci; Ahmed Elkashef
Journal:  Curr Opin Psychiatry       Date:  2005-05       Impact factor: 4.741

2.  Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats.

Authors:  Bernard Le Foll; Jorge Diaz; Pierre Sokoloff
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

3.  Topiramate for cocaine dependence.

Authors:  Joseph F Cubells
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

Review 4.  Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression?

Authors:  Athina Markou
Journal:  Biol Psychiatry       Date:  2006-07-28       Impact factor: 13.382

5.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

6.  Effects of acute topiramate dosing on methamphetamine-induced subjective mood.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang
Journal:  Int J Neuropsychopharmacol       Date:  2006-02-01       Impact factor: 5.176

Review 7.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

8.  Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

9.  Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Authors:  Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

10.  Role of training dose in discrimination of nicotine and related compounds by rats.

Authors:  I P Stolerman; H S Garcha; J A Pratt; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more
  8 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats.

Authors:  Yijin Yan; Abhiram Pushparaj; Yann Le Strat; Islam Gamaleddin; Chanel Barnes; Zuzana Justinova; Steven R Goldberg; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 3.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Topiramate increases the rewarding properties of cocaine in young-adult mice limiting its clinical usefulness.

Authors:  M C Arenas; A Mateos-García; C Manzanedo; M Rodríguez-Arias; M A Aguilar; F Navarrete; M S García Gutiérrez; J Manzanares; J Miñarro
Journal:  Psychopharmacology (Berl)       Date:  2016-09-05       Impact factor: 4.530

5.  Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex.

Authors:  V Echeverry-Alzate; E Giné; K M Bühler; J Calleja-Conde; P Olmos; M A Gorriti; R Nadal; F Rodríguez de Fonseca; J A López-Moreno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

6.  Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats.

Authors:  Zuzana Justinova; Sergi Ferré; Chanel Barnes; Carrie E Wertheim; Lara A Pappas; Steven R Goldberg; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2008-08-08       Impact factor: 4.530

7.  Low dose nicotine and antagonism of β2 subunit containing nicotinic acetylcholine receptors have similar effects on affective behavior in mice.

Authors:  Shawn M Anderson; Darlene H Brunzell
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration.

Authors:  Huimei Wei; Ting Zhang; Chang-Guo Zhan; Fang Zheng
Journal:  Neuropharmacology       Date:  2020-05-08       Impact factor: 5.273

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.